Indications and uses
relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor
do not use if individual foil pouch is open or torn store at 20°-25°C (68°-77°F) avoid excessive heat or humidity this product is sodium and sugar free
Drug Facts
Ranitidine 150 mg (as ranitidine hydrochloride 168 mg)
Acid reducer
Do not use if you are allergic to ranitidine or other acid reducers
Do not use
Ask a doctor before use if you have
Stop use and ask a doctor if
If pregnant or breast-feeding, ask a healthcare professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
hypromellose, magnesium stearate, microcrystalline cellulose, synthetic red iron oxide, titanium dioxide, triacetin
call
1-800-633-1610 or visit
www.zantacotc.com
Product repackaged and distributed by:
Lil' Drug Store Products, Inc.
9300 Earhart Lane SW, Cedar Rapids, IA 52404
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Ranitidine Hydrochloride | ACTIVE INGREDIENT | BK76465IHM | 2 | |
| Ranitidine | ACTIVE MOIETY | 884KT10YB7 | 2 | |
| Cellulose, Microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | 2 | |
| Ferric Oxide Red | INACTIVE INGREDIENT | 1K09F3G675 | 2 | |
| Hypromelloses | INACTIVE INGREDIENT | 3NXW29V3WO | 2 | |
| Magnesium Stearate | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| Titanium Dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| Triacetin | INACTIVE INGREDIENT | XHX3C3X673 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 66715-9736 | 66715-9736-2, 66715-9736-3, 66715-9736-8, 66715-9736-6 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYPROMELLOSE, UNSPECIFIED | 3NXW29V3WO | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| MICROCRYSTALLINE CELLULOSE | OP1R32D61U | IACT |
| FERRIC OXIDE RED | 1K09F3G675 | IACT |
| TITANIUM DIOXIDE | 15FIX9V2JP | IACT |
| TRIACETIN | XHX3C3X673 | IACT |
| RANITIDINE HYDROCHLORIDE | BK76465IHM | ACTIM |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / BUCCAL | 11 mg | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, DELAYED RELEASE / ORAL | 79 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FOR SUSPENSION / ORAL | 20100 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, COATED PELLETS / ORAL | 456 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, DELAYED RELEASE / ORAL | 1060 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| Ferric Oxide Red | FERRIC OXIDE RED | 1K09F3G675 | LOTION / TOPICAL | NA | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | LOTION / TOPICAL | NA | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | INSERT, EXTENDED RELEASE / OPHTHALMIC | 0.4 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | SUSPENSION, EXTENDED RELEASE / ORAL | 4 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, DELAYED RELEASE / ORAL | 23 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| Ferric Oxide Red | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, EXTENDED RELEASE / ORAL | 5 mg | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 221 mg | ||
| Ferric Oxide Red | FERRIC OXIDE RED | 1K09F3G675 | TABLET, FILM COATED / ORAL | 3 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GEL / TOPICAL | 0.06 %w/w | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | LOTION / TOPICAL | 0.1 %w/w | ||
| Ferric Oxide Red | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED / ORAL | 0.12 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | IMPLANT / INTRAVITREAL | 1.66 mg | ||
| Ferric Oxide Red | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE / ORAL | 5 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / ORAL | 72 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GRANULE, FOR SUSPENSION / ORAL | 143 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, EXTENDED RELEASE / ORAL | 1246 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 615 mg | ||
| Ferric Oxide Red | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 0.15 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, EXTENDED RELEASE / ORAL | 5119 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE / ORAL | 2169 mg | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | GRANULE, FOR SUSPENSION / ORAL | 1.7 mg | ||
| Ferric Oxide Red | FERRIC OXIDE RED | 1K09F3G675 | TABLET, CHEWABLE / ORAL | 2 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE, FOR SUSPENSION / ORAL | 278 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, COATED / ORAL | 1 mg | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | GRANULE / ORAL | 45 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | PASTE / DENTAL | 0.5 %w/w | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | PASTE, DENTIFRICE / DENTAL | 0.4 %w/w | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | SUSPENSION / OPHTHALMIC | 0.5 %w/w | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | SUSPENSION, EXTENDED RELEASE / ORAL | 1120 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / SUBCUTANEOUS | 0.5 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | GUM, CHEWING / BUCCAL | 182 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | CONCENTRATE / ORAL | 250 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | CAPSULE / ORAL | 1488 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / ORAL | 420 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SHAMPOO, SUSPENSION / TOPICAL | 3 %w/v | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 53 mg | ||
| Hypromelloses | HYPROMELLOSE | 3NXW29V3WO | SYSTEM / TOPICAL | 54 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY, EXTENDED RELEASE / INTRAUTERINE | 1 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| Cellulose, Microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / BUCCAL | 18 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021698-001 | ZANTAC 150 | RANITIDINE HYDROCHLORIDE | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | |
| N021698-002 | ZANTAC 150 | RANITIDINE HYDROCHLORIDE | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021698-001 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2004-08-31 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021698-002 | ZANTAC 150 | EQ 150MG BASE | TABLET / ORAL | RLD | 2007-03-13 | 4b0b4de00fa7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| b595216b-d636-7f28-e053-2a95a90a40bc | 5e569962-0763-4669-96c2-93012ff6cd6c | 2020-12-03 | Warnings | b595216b-d636-7f28-e053-2a95a90a40bc 5e569962-0763-4669-96c2-93012ff6cd6c |
Adverse event summaries are temporarily unavailable. Other product information remains available.